The forthcoming trial will also compare the consequences of two different doses of the new drug.

Medical trial advances cystic fibrosis therapy Axentis Pharma AG has initiated a clinical stage IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treating severe pulmonary an infection in cystic fibrosis individuals dianabol 25mg . The new formulation allows an established therapeutic agent to end up being delivered directly to the website of infection. The forthcoming trial will also compare the consequences of two different doses of the new drug. Initial email address details are expected in summer season 2009.